Intellia Therapeutics, Inc. (NTLA)
NASDAQ: NTLA · Real-Time Price · USD
11.84
+0.26 (2.25%)
At close: Oct 20, 2026, 4:00 PM EDT
11.92
+0.08 (0.68%)
After-hours: Oct 20, 2026, 7:57 PM EDT
Intellia Therapeutics Stock Forecast
Stock Price Forecast
According to 20 analysts polled by S&P Global, Intellia Therapeutics stock has a consensus rating of "Buy" and an average price target of $23.11. The average 1-year stock price forecast is 95.19% higher than the current stock price, while the lowest is $8.00 (-32.43%) and the highest is $61 (+415.20%).
Price Target: $23.11 (+95.19%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Intellia Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | May '26 | Jun '26 | Jul '26 | Aug '26 | Sep '26 | Oct '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 11 | 10 | 8 | 9 | 9 | 9 |
| Buy | 1 | 2 | 1 | 1 | 1 | 1 |
| Hold | 9 | 8 | 7 | 6 | 6 | 6 |
| Sell | 1 | 1 | 1 | 1 | 1 | 2 |
| Strong Sell | 1 | 1 | 2 | 2 | 2 | 2 |
| Total | 23 | 22 | 19 | 19 | 19 | 20 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wells Fargo | Wells Fargo | Hold Maintains $15 | Hold | Maintains | $15 | +26.69% | Oct 15, 2026 |
| Barclays | Barclays | Sell Initiates $8 | Sell | Initiates | $8 | -32.43% | Oct 6, 2026 |
| Wedbush | Wedbush | Hold Maintains $12 → $13 | Hold | Maintains | $12 → $13 | +9.80% | Sep 9, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $25 | Buy | Reiterates | $25 | +111.15% | Sep 9, 2026 |
| TD Cowen | TD Cowen | Buy Maintains n/a | Buy | Maintains | n/a | n/a | Sep 4, 2026 |
Financial Forecast
Revenue This Year
51.88M
from 67.67M
Decreased by -23.33%
Revenue Next Year
126.26M
from 51.88M
Increased by 143.36%
EPS This Year
-3.14
from -3.81
EPS Next Year
-2.56
from -3.14
EPS and Forward PE are based on non-GAAP adjusted numbers.